Abstract
BackgroundApolipoprotein M (apoM) is mainly enriched in high-density lipoprotein (HDL) cholesterol and is slightly present in low-density lipoprotein (LDL) cholesterol and very low-density lipoprotein cholesterol. apoM is involved in HDL formation and HDL-mediated reverse cholesterol transport. apoM is also associated with hyperlipidaemia and type 2 diabetes mellitus (T2DM). Significantly high plasma apoM levels are detected in hyperlipidaemia mice with a defective LDL receptor. By contrast, low plasma apoM levels are observed in patients with T2DM, which is often accompanied with hyperlipidaemia. However, the underlying mechanism of this condition is poorly understood. This research aims to examine the changes in apoM levels in patients with hyperlipidaemia and to determine the effects of hyperlipidaemia on plasma apoM levels in patients with T2DM.MethodsThis study included patients with hyperlipidaemia (n = 79), patients with T2DM but without hyperlipidaemia (n = 125), patients with T2DM and hyperlipidaemia (n = 98), and healthy controls (n = 105). Their plasma apoM concentrations were measured with enzyme-linked immunosorbent assay.ResultsThe average plasma apoM concentrations were 18 % higher in the hyperlipidaemia group (26.63 ± 10.35 ng/μL) than in the healthy controls (22.61 ± 10.81 ng/μL, P <0.01). The plasma apoM concentrations were lower in the T2DM without hyperlipidaemia group (18.54 ± 10.33 ng/μL, P <0.01) and the T2DM with hyperlipidaemia group (19.83 ± 7.41 ng/μL, P <0.05) than in the healthy controls. Similar to apoA-I (1.29 ± 0.33 g/L vs. 1.28 ± 0.31 g/L, P >0.05), the plasma apoM concentrations in the T2DM with hyperlipidaemia group did not significantly differ from those in the T2DM without hyperlipidaemia group (P >0.05). Multivariate linear regression analysis showed that hyperlipidaemia (β = 5.18, P = 0.007) is an independent promoting factor of plasma apoM levels and diabetes (β = −3.09, P = 0.005) is an inhibiting factor of plasma apoM levels.ConclusionPlasma apoM concentrations are higher in patients with hyperlipidaemia than in healthy controls. Low plasma apoM levels in patients with T2DM are likely caused by diabetes but are not induced by hyperlipidaemia.
Highlights
Apolipoprotein M is mainly enriched in high-density lipoprotein (HDL) cholesterol and is slightly present in low-density lipoprotein (LDL) cholesterol and very low-density lipoprotein cholesterol. apoM is involved in HDL formation and HDL-mediated reverse cholesterol transport. apoM is associated with hyperlipidaemia and type 2 diabetes mellitus (T2DM)
This study aimed to examine the apoM levels in patients with hyperlipidaemia, patients with T2DM and hyperlipidaemia, and patients with T2DM but without hyperlipidaemia through enzyme-linked immunosorbent assay (ELISA)
systolic blood pressure (SBP), diastolic blood pressure (DBP), and plasma FPG levels were higher, whereas superoxide dismutase (SOD), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and apoM complex also contains HDL-C (apoA-I) levels were lower in the T2DM without hyperlipidaemia group compared with healthy controls
Summary
Apolipoprotein M (apoM) is mainly enriched in high-density lipoprotein (HDL) cholesterol and is slightly present in low-density lipoprotein (LDL) cholesterol and very low-density lipoprotein cholesterol. apoM is involved in HDL formation and HDL-mediated reverse cholesterol transport. apoM is associated with hyperlipidaemia and type 2 diabetes mellitus (T2DM). High plasma apoM levels are detected in hyperlipidaemia mice with a defective LDL receptor. Low plasma apoM levels are observed in patients with T2DM, which is often accompanied with hyperlipidaemia. Hyperlipidaemia is often accompanied with complex dyslipidaemia, such as increased LDL-C and VLDL-C levels and low HDL-C levels, which are associated with plasma apoM [6]. Increased plasma triglyceride (TG) levels and significantly high plasma apoM levels are detected in hyperlipidaemia mice with defective low-density lipoprotein (LDL) receptor [7]. This observation suggests that plasma apoM concentrations may change in patients with hyperlipidaemia. The specific effect of hyperlipidaemia on plasma apoM in patients with T2DM should be investigated to confirm whether low plasma apoM levels in T2DM are caused by diabetes or hyperlipidaemia
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
